Med-IQ
Pediatric Neurogenic Detrusor Overactivity: Exploring a Changing Treatment Landscape and Building Successful Patient, Caregiver, and Provider Teams

Pediatric Neurogenic Detrusor Overactivity: Exploring a Changing Treatment Landscape and Building Successful Patient, Caregiver, and Provider Teams

Med-IQ Select
Continue to Course
Online Course | Specialties: Pediatrics, Urology
Released: 3/22/2022
|
Expires: 3/21/2023
|
Max Credits: 0.5
Continue to Course Read Abstract

Faculty
Renea Sturm, MD, FAAP
Assistant Professor, Department of Urology
David Geffen School of Medicine
University of California, Los Angeles
Pediatric Urologist
UCLA Mattel Children’s Hospital
UCLA Santa Monica Hospital
Los Angeles, CA

Activity Planners
Kia Jones, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Writer
Anne Jacobson, MSPharm, CHCP
Cocoa Beach, FL

Learning Objectives
Upon completion, participants should be able to:

  • Identify a systematic approach to the evaluation and diagnosis of NDO
  • Incorporate the latest data on newly approved therapies regarding efficacy, benefits, adherence, and drawbacks, as well as patient and caregiver preferences/perspectives, into individualized management plans for NDO
  • Employ a successful team-based (ie, patients, families, and healthcare professionals) approach that individualizes care and educates and empowers patients

Target Audience
This activity is intended for pediatric urologists, urologists, and pediatricians.

Statement of Need
Untreated pediatric neurogenic detrusor overactivity (NDO) is associated with significant morbidity, mortality, and reduced quality of life, underscoring the importance of prompt evaluation and diagnosis. For children, incontinence can have a monumental effect on successful social participation and peer relationships. Adherence to existing antimuscarinic/anticholinergic therapies, which have formed the mainstay of pharmacologic treatment, is low, and these agents are not approved by the Food and Drug Administration for use in children younger than 5 years. Recent additions to the treatment landscape for pediatric NDO highlight the need for clinicians to be aware of the latest data surrounding these agents and their place in the armamentarium for NDO in children. It is also imperative that clinicians work with children and caregivers as a cohesive unit to address their needs and goals and empower and educate them to help diminish the stigma surrounding incontinence.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
This is a 0.5-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: March 22, 2022
Expiration Date: March 21, 2023
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Renea Sturm, MD, has indicated no real or apparent conflicts.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CME
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Astellas.

Copyrighted

The following material has been developed to accompany this activity:

Pediatric Neurogenic Detrusor Overactivity: A Practical Guide for Parents and Caregivers


Note: This material is not accredited for CME and, therefore, does not offer any CME/CE credit.

Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • NDO, a type of bladder dysfunction caused by neurologic conditions, is characterized by uninhibited bladder contractions that can lead to symptoms of urinary frequency, urgency, and incontinence
  • Approximately 85% of children with NDO have spina bifida; other associated neurologic conditions include transverse myelitis, cerebral palsy, spinal cord tumors, and spinal cord injuries
  • Untreated NDO is associated with significant morbidity, mortality, and reduced quality of life, underscoring the importance of prompt evaluation, diagnosis, and therapeutic intervention designed to support independence and protect psychosocial functioning
  • New additions to the treatment landscape for NDO include mirabegron (for the treatment of NDO in children aged 3 years or older) and onabotulinumtoxinA (for pediatric patients aged 5 years or older who have an inadequate response to or are intolerant of anticholinergic medication)
  • Continence is a large part of children’s social development and a major determinant of independence; therefore, it is imperative that clinicians work with children and caregivers as a cohesive unit to address their needs and goals, as well as empower and educate them to help diminish the stigma surrounding continence issues

View reference list.

Click “Continue” to proceed through this activity and/or receive credit.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.